Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (11909)	1/22/2003 9:22:41 AM
From: Claude Cormier	Read Replies (1) \| Respond to of 14101

Is this significant? Globe says Dimethaid director Sooley unloads shares The Globe and Mail reports in its Wednesday, Jan. 22, edition that Dimethaid Research director Daniel Sooley sold 22,700 common shares in the drug development company on Dec. 4, according to the latest insider trading reports filed with the Ontario Securities Commission. The Globe's Insider Trading column reports that Mr. Sooley sold the shares at prices between $2.75 and $2.82 to reduce his holdings to 14,361 shares. Also during December, Mr. Sooley sold an additional 74,100 shares held indirectly, at prices between $2.58 and $3.02, to reduce his indirect holdings to 20,500 shares. Dimethaid stock slipped 15 cents to close at $2.32 on the Toronto Stock Exchange Tuesday. The stock has a relatively wide 52-week trading range of $6.10 to $1.47. Looks to me like recent news will have only one effect, to cause price drop in the stock.